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Introduction: Retaining clients in residential alcohol and other drug (AOD) treatment is difficult and
cognitive impairment has been identified as a significant predictor of treatment dropout. The application of
extensive screening for cognitive impairment is cost-prohibitive for most AOD treatment services. The
current study aimed to explore cognitive functioning and impairment-associated factors in a typical sample of
residential AOD clients using a free brief screening tool that could be utilised by front-line AOD services.
Methods: Residents of an AOD therapeutic community (n = 128) and a non-substance using control group
(n = 37) were administered a brief cognitive screening measure, the Montreal Cognitive Assessment (MoCA).
MoCA total and domain scores were compared between these groups and within the AOD group examined in
association with primary substance of misuse, severity of dependence, gender, psychological distress, and
history of head injury. Results: Almost half (43.8%) of the AOD sample were identified as cognitively
impaired, compared to 16.2% of the control group. Furthermore, 67.2% of the AOD sample had sustained
head injuries and 50% of the sample required hospitalization for head injury. History of head injury was a
significant determinant of cognitive impairment, and associated with greater levels of psychological distress.
Conclusions: There are high rates of inter-related cognitive impairment, head injuries, and psychological
distress among clients in residential AOD treatment. Routine screening of clients at intake for cognitive
impairment by means of a brief screening measure such as the MoCA, in combination with the assessment of
history of head injuries and comorbid psychological disorders, could inform treatment modifications or
adjunct interventions to increase retention and improve long-term outcomes.
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Abstract
Introduction
Retaining clients in residential alcohol and other drug (AOD) treatment is difficult and
cognitive impairment has been identified as a significant predictor of treatment dropout. The
application of extensive screening for cognitive impairment is cost-prohibitive for most AOD
treatment services. The current study aimed to explore cognitive functioning and impairmentassociated factors in a typical sample of residential AOD clients using a free brief screening
tool that could be utilised by front-line AOD services.
Methods
Residents of an AOD therapeutic community (n = 128) and a non-substance using control
group (n = 37) were administered a brief cognitive screening measure, the Montreal
Cognitive Assessment (MoCA). MoCA total and domain scores were compared between
these groups and within the AOD group examined in association with primary substance of
misuse, severity of dependence, gender, psychological distress, and history of head injury.
Results
Almost half (43.8%) of the AOD sample were identified as cognitively impaired, compared
to 16.2% of the control group. Furthermore, 67.2% of the AOD sample had sustained head
injuries and 50% of the sample required hospitalisation for head injury. History of head
injury was a significant determinant of cognitive impairment, and associated with greater
levels of psychological distress.
Conclusions
There are high rates of inter-related cognitive impairment, head injuries, and psychological
distress among clients in residential AOD treatment. Routine screening of clients at intake for
cognitive impairment by means of a brief screening measure such as the MoCA, in
combination with the assessment of history of head injuries and comorbid psychological
disorders, could inform treatment modifications or adjunct interventions to increase retention
and improve long-term outcomes.

Key words: substance misuse; cognitive impairment; therapeutic community; residential
treatment; cognitive screening; head injury
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1. Introduction
Therapeutic communities (TCs) are a form of residential rehabilitation for individuals
experiencing chronic and severe alcohol and other drug (AOD) problems and may
particularly suit clients with associated comorbidities and other complexities as they place an
emphasis on fostering social support within the community of residents in order to promote
treatment engagement and completion. Dropout from AOD treatment in general is estimated
to be as high as 57% in inpatient settings (Darke, Campbell, & Popple, 2012a; Deane,
Wootton, Hsu, & Kelly, 2012; Vergara-Moragues, Gonzalez-Saiz, Lozano, & Verdejo
Garcia, 2013). Importantly, length of stay in TCs has been shown to be related to
neurocognitive capacity (Fals-Stewart & Lucente, 1994; Fals-Stewart & Schafer, 1992;
Fernández-Serrano, Pérez-García, Perales, & Verdejo-García, 2010a). An extensive
systematic review reported that cognitive deficits were one of the most consistently reported
risk factors for dropout from AOD treatment, alongside personality disorder, low treatment
alliance, and younger age (Brorson, Ajo Arnevik, Rand-Hendriksen, & Duckert, 2013).
It is likely that most residential substance misuse programs deliver treatments that
work optimally in those who possess intact cognitive abilities; that cognitive impairment
among residents may hinder treatment success requires further consideration. Components of
residential AOD treatment often rely on capacities such as executive function (defined
broadly as “those capacities that enable a person to engage successfully in independent,
purposive, self-directed, and self-serving behavior”; Lezak, Howieson, Bigler, & Tranel,
2012, p. 37) and working memory (Fernández-Serrano et al., 2010b; Yücel & Lubman,
2007), as clients are required to integrate new information, formulate goals, establish new
behavioural strategies, and plan for the future in overcoming addiction.
However, most misused substances impair attention, learning and memory,
visuospatial abilities, and executive functioning, with perhaps the most robust deficits across
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all substances evident in inhibitory control, working memory, and decision-making
(Fernández-Serrano, Pérez-García, Río-Valle, & Verdejo-García, 2010b; Yücel & Lubman,
2007; Yücel, Lubman, Solowij, & Brewer, 2007). Structural and functional brain changes
may occur after substance misuse (Broyd, van Hell, Yücel, & Solowij, in press; Caplan,
Epstein, Quinn, Stevens, & Stern, 2007; Ersche & Sahakian, 2007; Gonzalez, 2007; Gruber,
Silveri, & Yurgelun-Todd, 2007; Lorenzetti, Solowij, & Yücel, in press; Oscar-Berman &
Marinkovic, 2007; Scott et al., 2007). Traumatic brain injury (TBI) is also highly prevalent in
substance misuse populations, leading to significant complexities in the process of AOD
treatment (Sacks et al., 2009; Solomon & Malloy, 1992; Walker, Cole, Logan, & Corrigan,
2007; West, 2011).
Although cognitive dysfunction is common in AOD samples and increasingly
recognised by staff, there is often insufficient time or resources to implement detailed
neuropsychological assessments. Cognitive assessment may be instrumental in facilitating the
detection of AOD clients with clinically significant cognitive impairment, irrespective of
aetiology. Assessing clients’ cognitive capacities can inform subsequent implementation of
strategies aimed at improving treatment retention and outcomes.
In the AOD treatment environment a brief but valid and reliable measure is required.
This would provide an indication of potential cognitive dysfunction and alert staff to the
possibility that further neuropsychological assessment and/or treatment modifications may be
indicated. The Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005) comprises
12 items that tap five key neuropsychological domains: executive function, working memory,
short-term memory, language, and visuospatial ability. The MoCA takes 15 minutes to
administer, is a free resource (Nasreddine, 2014), and can be administered by staff without
formal neuropsychological training. Initial studies have found evidence supporting the use of
the MoCA in AOD treatment settings (Copersino et al., 2009; Copersino et al., 2012).
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The current study was exploratory in nature and sought to provide a naturalistic
overview of a sample of Australian TC residents, with the MoCA administered as a brief
screening measure to assess neuropsychological functioning. Performance on the MoCA was
investigated in relation to demographic, substance use, psychological, and other variables
related to impairments in cognition, including TBI.

2. Material and methods
2.1 Participants
The AOD group was recruited from We Help Ourselves (WHOs), a large provider of
residential AOD treatment in Australia that uses the Therapeutic Community model of
treatment. Participants were recruited across seven WHOs sites in New South Wales
(Sydney, Hunter Valley) and Queensland (Sunshine Coast). The response rate was
approximately 90%. Specific inclusion and exclusion criteria were not applied in order to
capture the heterogeneous and complex presentations of residential AOD treatment
populations and to increase the generalisability of results. Although there was no formal
assessment of substance use disorders using the Diagnostic and Statistical Manual of Mental
Disorders (5th ed.; DSM–5; American Psychiatric Association, 2013) criteria it was assumed
that residents would meet these criteria given their attendance at a high-intensity residential
program.
A control group was recruited through University of Wollongong College, a provider
of educational programs to persons who have not completed highschool matriculation, as an
alternative pathway to tertiary study. All students were invited to participate and the response
rate was approximately 60%. Control participants, all native English speakers, were excluded
for any lifetime dependence on or treatment for alcohol or other drugs, and any psychiatric or
neurological diagnoses.
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2.2 Procedure
After a group information session, interested participants provided written consent
and were individually assessed in a quiet testing room. This was conducted within the TC
facility for the AOD group, and at a University psychology clinic for the control group. The
MoCA was administered in approximately 15 minutes, adhering to the administration and
scoring guidelines (Nasreddine, 2014). Additional information (e.g., basic demographics,
history of head injury, current and past substance use for controls) was obtained through a
ten-minute semi-structured interview and the Kessler Psychological Distress Scale (K10;
Kessler et al., 2002) was administered, as well as the Severity of Dependence Scale (SDS;
Gossop et al., 1995) for the AOD group. Control participants received a $20 gift card as
reimbursement for their time.
2.3 Measures
2.3.1 MoCA
The MoCA was used to assess neuropsychological functioning across its purported
five domains (executive function, working memory, short-term memory, language and
visuospatial ability). Executive function is assessed using trail-making, phonemic fluency,
and verbal abstraction tasks. Working memory is assessed using sustained attention, serial
subtraction, and digit span forwards/backwards tasks. Short-term memory is assessed through
the delayed recall of five nouns. Language is assessed using naming (low familiarity
animals), sentence repetition, and the phonemic fluency task. Visuospatial ability is assessed
using clock-drawing and cube-copying tasks. The MoCA has displayed acceptable reliability
in clinical groups (Bernstein, Lacritz, Barlow, Weiner, & DeFina, 2011; Freitas, Simões,
Marôco, Alves, & Santana, 2012). Outcome measures included total MoCA score and
domain subscores.
2.3.2 Clinical variables
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The SDS (Gossop, Best, Marsden, & Strang, 1997) measured AOD participants’ level
of dependence on their primary substance of misuse. The K10 was used to capture level of
psychological distress experienced by all participants. The K10 has been extensively used in
both community and clinical samples as an indicator of a potential psychological disorder,
and has demonstrated acceptable psychometric properties (George, Kinner, Bruno,
Degenhardt, & Dunn, 2010; Hides et al., 2007; Sunderland, Mahoney, & Andrews, 2012).
Relevant demographic and substance use data routinely collected by WHOs were accessed,
following participants and the director of the service providing written consent.
2.4 Data analysis
All data were analysed using IBM Statistical Package for the Social Sciences (version
19; IBM Corp, 2010). The primary goals of the analysis were to compare the performance of
residents and controls on the MoCA and to explore variation in MoCA scores and potential
predictors (e.g., primary substance of misuse, gender effects) within the AOD sample.
Shapiro-Wilk statistics and visual inspection of histograms and boxplots determined
that total MoCA score, MoCA domain subscores, age, years of education, K10 and SDS
scores were not normally distributed for both AOD and control groups. Consequently,
nonparametric techniques were employed for most of the analyses. Nonparametric analysis of
covariance was required for some analyses to enable covarying demographic characteristics
that differed between groups. Quade’s (1967) distribution-free procedure was used as a
nonparametric alternative to analysis of covariance (see Olejnik & Algina, 1985). This
involved ranking the dependent variable and all covariates for all cases, ignoring the grouping
variable. Following this, the linear regression of the ranked dependent variable on the ranked
covariate measure was calculated and the unstandardised residuals saved, again ignoring the
grouping factor. To calculate Quade’s F statistic, a one-way analysis of variance using the
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residuals from the regression as the dependent variable and the grouping variable as the factor
was performed.
Total MoCA score and cognitive domain subscores were the primary dependent
variables for analysis. However, factor analyses of the MoCA have demonstrated that
domains may be grouped differently (e.g., Duro, Simões, Ponciano, & Santana, 2010; Freitas
et al., 2012). Given the multi-process nature of neuropsychological tasks, whereby any single
task may tap into a range of perceptual, cognitive and motor abilities, and the overlapping
nature of the cognitive domains assessed by the MoCA (Freitas et al., 2012), we created an
additional score for analysis of executive function. This was of particular interest because
executive dysfunction is especially common in substance misusing individuals (e.g.,
Fernández-Serrano et al., 2010b; Gierski et al., 2013; Hester, Lubman, & Yϋcel, 2010; Perry
et al., 2011). As such, we utilised the standard measure of executive function from the MoCA
as well as an extended measure that included performance on the visuospatial cube-copying
and clock-drawing tasks, with the rationale that these tasks rely on key component processes
of executive function.
All AOD residents were compared to controls in the first instance. Residents were
then compared in terms of gender and primary substance of misuse. Primary substance of
misuse groupings were formed by choosing the three largest representative groups in
residence at the time of testing (alcohol, heroin and amphetamines). A broader opiates group
was then formed by the addition of clients on methadone maintenance and buprenorphine
users. Cocaine users, minimal in Australian AOD samples (Australian Institute of Health and
Welfare, 2005), were grouped with amphetamine users to form a stimulants group. This
strategy maximised group sizes for comparison, grouping together substances with similar
chemical properties. However, primary users of cannabis, tranquilisers and benzodiazepines
were not grouped or included in these comparisons due to insufficient sample sizes of these
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subgroups (see Results). Finally, AOD users hospitalised after a head injury were compared
to those without serious head injuries.

3. Results
3.1 Preliminary analyses
MoCA data were available for 128 AOD residents and 37 controls. For some
analyses, the AOD sample was reduced to 95 due to missing data (e.g. primary substance of
misuse, n=16; SDS and K10 scores, n=33). Table 1 displays demographic, substance use,
psychological, and cognitive functioning variables for the AOD group. AOD residents were
in their mid-thirties on average and predominantly male. Alcohol was the primary substance
of misuse for almost one-third of the sample, followed by heroin and amphetamine misuse,
with these three substances accounting for approximately 80% of the entire AOD sample.
The mean K10 score indicated very high levels of psychological distress and the mean SDS
score indicated high levels of psychological dependence on participants’ primary substance
of misuse, although the range extended to 0 in some cases, reflecting that some residents had
progressed further in their treatment. The prevalence of head injuries was particularly high in
the sample. Of the 67.2% who had either lost consciousness or sustained a concussion after a
head injury, the mean number of times this had occurred was 4.98 (SD = 5.95). Half of the
total sample had been hospitalised after sustaining a head injury.
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Table 1
Demographic, substance use, psychological, and clinical variables for the AOD group (N = 128)
Age (Mdn, range)

35 (19-56)

Gender (% male)

70.3

Education (Mdn, range)

10 (7-16)

Unemployed (%)

90.5

a

Homeless (%)

7.4
a

Arrested during last three months (%)

43.2

b

Primary substance of misuse (%)

c

Alcohol

30.4

Heroin

27.7

Amphetamines

20.5

Cannabis

8.9

Tranquilisers

4.5

Methadone

2.7

Buprenorphine

1.8

Cocaine

1.8

Benzodiazepines

1.8

a

SDS score (Mdn, range)

11 (0-15)

History of overdose (%)

60.2

Injected during last three months (%)

52.6

d

a

K10 score (M, SD)

29.2 (7.8)

Hospitalised after head injury (%)

50

Lost consciousness/concussion after head injury (%) 67.2
a

N = 95
N = 112.
c
Severity of Dependence Scale.
d
Kessler Psychological Distress Scale.
b

All control participants were screened to ensure that they had not been dependent on
alcohol or other substances and/or received treatment for substance use disorder in the past.
No control participant currently used any substance (excluding alcohol and tobacco) on a
regular basis (i.e., greater than once a month), with minimal prior experimentation with
drugs, and 76% drank alcohol less than twice per week. The 24% of control participants who
drank alcohol more than once per week were screened to ensure that their current drinking
was not occurring at a problematic level that caused clinically significant impairment or
distress. Despite attempts to match sample characteristics, controls were significantly
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younger (Mdn = 25 years, range 21-61) than the AOD group (Mdn = 35 years, range 19-56),
z = -5.21, p < .001, and had significantly more years of education (Mdn = 12 years vs. Mdn =
10 years), z = -4.26, p < .001. Gender distribution did not differ significantly between groups
(54% male in controls vs. 70.3% male in AOD). Age and education were therefore included
as covariates for group comparisons. Psychological distress was low to moderate in controls
(K10 mean 17), and was significantly higher in AOD residents (K10 mean 29), F(1, 130) =
33.33, p = < .001.
3.2 Primary analyses
3.2.1 Covariates
Despite the group difference in age, age was not significantly correlated with total
MoCA score, p = .16. It was also not correlated with any MoCA subscores, all p > .05, in the
entire sample as well as in the AOD group alone. There were significant correlations between
years of education and total MoCA score, r = .18, p = .02, executive function, r = .36, p <
.001, short-term memory, r = .18, p = .02, working memory, r = .21, p = .006, and language,
r = .26, p = .001. Age and education were both included as covariates in analyses, but while
education was consistently significant in the models, age was not. Age was subsequently
dropped from the analyses and results are reported here with education alone as the covariate
in analyses of MoCA outcomes for the AOD vs. control group.
3.2.2 MoCA scores
Comparison of the AOD and control group determined a significant difference in total
MoCA score, F(1, 163) = 5.28, p = .023, the combined executive function/visuospatial
subscore, F(1, 163) = 6.91, p = .009, and the visuospatial domain alone, z = -2.43, p = .015,
with poorer performance in the AOD group (Table 2). None of the other cognitive domain
subscores differed between groups: short-term memory, F(1, 163) = .25, p = .62, working
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memory, F(1, 163) = .27, p = .60, and language, F(1, 163) = 1.04, p = .31. There was a trend
toward poorer executive function in the AOD group, F(1, 163) = 3.01, p = .08.
Table 2
Comparison of MoCA scores between AOD and control groups, for entire AOD sample and those without head
injuries: mean (SD)

Total score

Head Injuries included

Head injuries excluded

AOD group (N = 128)

AOD group (N = 64)

Control (N = 37)

25.60 (3.13)*

26.39 (2.56)

26.94 (3.10)

Executive/Visuospatial

5.13 (1.57)**

5.53 (1.47)

6.14 (1.64)

Executive

2.48 (1.05)

2.73 (1.03)

3.08 (0.92)

a

3.63 (1.33)

3.78 (1.23)

3.92 (1.23)

b

5.36 (1.06)

5.50 (1.04)

5.43 (0.99)

Visuospatial

2.64 (1.01)*

2.80 (0.98)

3.05 (1.13)

Language

5.01 (0.94)

5.16 (0.88)

5.35 (0.82)

STM
WM

*p < .05 **p < .01
a
Short-term memory
b
Working memory

3.2.3 Gender effects
There were no significant differences between male and female AOD participants in
age, years of education, or SDS scores (all p > .28). Females tended to have higher K10
scores (M = 31.25, SD = 7.89) than males (M = 28.21, SD = 7.60), t(93) = -1.82, p = .07.
MoCA outcomes for males vs. females were not significantly different (all p > .10) although
females tended to score slightly higher than males (Mdn 3 vs. 2) on executive subscores, z = 1.68, p = .09.
3.2.4 Primary substance of misuse
There were significant differences between primary substance of misuse groups in
age, F(2, 92) = 8.25, p = .001, but not years of education, H(2) = 4.15, p = .13, or SDS scores,
H(2) = 1.59, p = .45; age was therefore included as a covariate in the analysis. There were no
significant differences in total MoCA score, F(2, 92) = .04, p = .96, short-term memory, F(2,
92) = .09, p = .92, language, F(2, 92) = .15, p = .86, executive function, F(2, 92) = 1.37, p =

Journal of Substance Abuse Treatment 2016 66: 30-36

13

.26, visuospatial abilities, F(2, 92) = 1.61, p = .21, or

combined executive

function/visuospatial abilities, F(2, 92) = 1.30, p = .28, between primary substance of misuse
groups (Table 3). There was a marginally significant difference for working memory
performance, F(2, 92) = 2.98, p = .056, with the poorest performance in the stimulants group.
K10 scores were significantly different across substance of misuse groups, F(2, 77) = 5.96, p
= .004, being higher in the stimulant group relative to the opiate group (p = .022) and the
alcohol group (p = .07), with no difference between alcohol and opiate groups (p = .69).
Table 3
Comparison of MoCA scores across primary substance of misuse groups: mean (SD)

Alcohol (N = 34)

Opiates (N = 36)

Stimulants (N = 25)

25.85 (3.49)

25.92 (2.55)

25.88 (3.23)

Executive/Visuospatial

5.09 (1.73)

5.14 (1.51)

5.60 (1.58)

Executive

Total score

2.26 (1.14)

2.64 (1.05)

2.68 (1.11)

a

3.76 (1.18)

3.69 (1.35)

3.64 (1.31)

b

5.53 (1.08)

5.56 (0.69)

5.00 (1.22)

Visuospatial

2.82 (0.94)

2.50 (1.06)

2.92 (0.91)

Language

5.12 (0.95)

4.94 (1.01)

4.96 (0.93)

STM
WM

a
b

Short-term memory.
Working memory; trend toward greater impairment in the stimulants group p=.056.

3.3 Exploratory analyses
3.3.1 Psychological distress and substance dependence
There were significant negative correlations between K10 scores and total MoCA
scores, r = -.22, p = .012, executive function/visuospatial abilities, r = -.21, p = .015, and
language scores, r = -.20, p = .021, and a trend for working memory, r = -.16, p = .06, in the
overall AOD sample. K10 and SDS scores were positively correlated, r = .20, p = .049, but
SDS scores were not correlated with any MoCA scores (all p > .05), other than a trend toward
a correlation with executive function, r = .18, p = .085. This pattern indicates that greater
psychological distress (but not greater drug dependence) is associated with greater cognitive
impairment.
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3.3.2 Head injuries
Given that 50% of the AOD sample had been hospitalised for a head injury, the
impact of head injuries on cognitive function were imperative to investigate further. There
were no significant differences in age, z = -1.24, p = .22, education, z = -.94, p = .35, or K10
scores, t(93) = -.23, p = .82, between AOD residents who had versus had not been
hospitalised after a head injury, but those who had not been hospitalised for head injury had
higher SDS scores, z = -2.10, p = .035, (Mdn = 11 vs. 10). AOD participants who had been
hospitalised had lower total MoCA scores (Mdn = 25.5 vs. 26), z = -2.59, p = .01, than those
who had not. The hospitalised group also had lower executive/visuospatial (Mdn = 5 vs. 6, z
= -2.97, p = .003), working memory (Mean Rank = 58.38 vs. 70.62, z = -2.18, p = .03), and
executive (Mdn = 2 vs. 3, z = -2.66, p = .008) subscores, than the non-hospitalised group,
with trends toward lower language, z = -1.67, p = .095, and visuospatial subscores, z = -1.71,
p = .088, but no difference in short-term memory subscores, z = -1.17, p = .24. Figure 1
displays standardised (out of 6) MoCA domain scores for AOD participants hospitalised for
head injuries, non-hospitalised AOD participants and controls.
3.3.3 Analysis of sample without significant head injuries
After exclusion of those who had been hospitalised after a head injury, the primary
analyses were repeated to compare only those AOD residents who had not sustained head
injures requiring hospitalisation with controls (Table 2). The AOD group in this reduced
sample (n = 64) were significantly older than controls (Mdn = 34 vs. 25, respectively), z = 4.82, p = < .001, and less educated (Mdn = 10 vs. 12), z = -3.65, p = < .001. With age and
education included as covariates, there were no significant differences in total MoCA score,
F(1, 99) = .38, p = .54, or any MoCA subscores (all p > .20) between AOD residents without
significant head injuries and controls. Significant differences remained for K10 scores
between these AOD residents (Mdn = 29) and controls (Mdn = 16), F(1, 82) = 33.51, p = <
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.001. Other than males scoring significantly higher (Mean Rank = 36.43) in working memory
subscores than females (Mean Rank = 25.50), z = -2.91, p = .004, no other effects of gender
or primary substance of misuse were found in this sample without head injuries.
3.3.4 Clinical significance of impairment
To investigate the clinical significance of impairment, total MoCA scores were
recoded as a dichotomous variable to indicate either the presence or absence of cognitive
impairment according to the cut-off score suggested by Copersino et al. (2009) as ≥ 26
reflecting no evidence of cognitive impairment. Within the overall AOD group, 43.8% met
criteria for cognitive impairment. After removing those hospitalised for head injuries, 37.5%
met criteria for impairment and this represented a significantly greater proportion than the
16.2% of controls meeting criteria for impairment, χ²(1, N = 101) = 5.09, p = .019. However,
after removing a further 27 participants in the AOD sample who had sustained concussion or
lost consciousness after a head injury but had not been hospitalised, the prevalence of
impairment dropped to 29.7% and this did not represent a statistically significant difference
when compared to the 16.2% of impaired controls (p = .13). Subsequently, it was deemed
appropriate to examine the prevalence of impairment within the AOD group who had been
hospitalised after a head injury. Of those who had been hospitalised (n = 64), only 50% met
criteria for cognitive impairment, indicating that hospitalisation for head injuries alone may
not predict cognitive impairment. There was no difference in the total number of head
injuries (including those that did not require hospitalisation) sustained by those who met
criteria for impairment (Mdn = 3) vs. those who did not (Mdn = 3), p = .67.

4. Discussion
This study used a brief screening tool, the MoCA, to provide an overview of cognitive
functioning in residents of a substance misuse TC. The major findings were that 43.8% of the
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AOD group met criteria for cognitive impairment and head injuries were a significant
determinant of this impairment. Within the AOD group, 50% had been hospitalised after a
head injury and were more cognitively impaired than those who had not sustained head
injuries requiring hospitalisation. Greater psychological distress in the AOD group was also
associated with greater cognitive deficits.
4.1 Neuropsychological functioning
AOD residents overall scored significantly lower on the MoCA and showed greater
deficits in executive function and visuospatial abilities than controls. No other cognitive
domains differed between residents and controls. Within the AOD group, there were no
gender effects other than a trend toward males displaying greater executive dysfunction than
females and females tended to have higher levels of psychological distress than males. MoCA
outcomes did not differ according to primary substance of misuse, other than stimulant users
showing marginally poorer working memory ability and higher levels of psychological
distress. The lack of observed differences in neuropsychological outcomes between substance
of misuse groups may be explained by the prevalence of polysubstance use in clients
undergoing residential AOD treatment; differences may not be detected between groups in
which substance use has reached a level necessitating residential treatment. Generally, clients
in residential AOD treatment have extensive histories of substance use with considerable
variability between individuals. Another possible explanation is that differences do exist
between substance of misuse groups in residential treatment but that the current study did not
possess group sizes large enough to detect these differences.
4.1.1 Head injuries
Half of the AOD sample in the current study had been hospitalised after a head injury
and were more cognitively impaired than those who had not, with lower total MoCA scores,
and poorer executive/visuospatial and working memory abilities. When the hospitalised
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group were excluded from the analysis, there were no differences in any neuropsychological
outcomes between AOD residents and controls, and no differences between primary
substance of misuse groups, but females in this subset displayed poorer working memory
performance than males.
In general, these findings are congruent with the literature suggesting that cognitive
impairments exist in AOD populations (Caplan et al., 2007; Ersche & Sahakian, 2007;
Fernández-Serrano et al., 2010b; Gonzalez, 2007; Gruber et al., 2007; Oscar-Berman &
Marinković, 2007; Scott et al., 2007; Yücel & Lubman, 2007; Yücel et al., 2007) and may be
detected by a brief cognitive impairment-screening tool (the MoCA). In assessing a
residential AOD sample, arguably we accessed those most severely affected by their
addiction, and also those with a high prevalence of head injuries requiring hospitalisation.
The level of cognitive impairment detected in this sample, as measured by the MoCA, was
not severe and was largely associated with TBI, a factor that has not routinely been
considered in previous studies and may account for a significant portion of the deficits
observed in the literature.
4.2 Implications
This study showed that having sustained a TBI requiring hospitalisation accounted for
the majority of cognitive impairment detected in the sample. There are two major
implications: first, simply asking clients whether they have ever sustained a head injury
requiring hospitalisation may be the most time-efficient way to informally gauge the
possibility of cognitive deficits. Clients may be unable, however, to provide accurate
accounts due to the high rate of TBIs occurring during intoxication that may remain
undetected and receive no medical intervention. Whilst half of the AOD group in the current
study had sustained a head injury requiring hospitalisation, 50% of this subgroup did not
meet criteria for impairment based on the MoCA score threshold. As such, screening for head
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injuries alone without subsequent cognitive assessment may lead to inflated estimates of
impairment. Furthermore, this type of screening would not capture approximately one third of
the AOD sample that had never sustained head injuries and yet met criteria for cognitive
impairment. Thus, the second implication is that cognitive deficits may also exist
independently of head injuries in AOD samples and hence require screening in their own
right.
These complex findings highlight the importance of brief cognitive screening as a
standardised assessment procedure for all clients entering residential treatment. In this way,
treatment planning may account for the presence of cognitive deficits. Further
neuropsychological assessment may be recommended and modifications to treatment and/or
targeted interventions may be implemented.
Regardless of the aetiology of cognitive impairment, cognitive screening has the
potential to inform interventions aimed at alleviating these deficits. For example, adjunct
interventions to remediate cognitive deficits together with better-tailored specific treatments
may bolster residential services, reducing dropout rates and consequently improving
treatment outcomes. Evidence suggests that the neuropsychological deficits associated with
TBI can be alleviated through cognitive remediation interventions (Maas et al., 2013; Manley
& Maas, 2013; Tsaousides & Gordon, 2009), and there is emerging evidence for the use of
cognitive remediation programs in substance misuse populations as a way to improve
treatment retention (Bates, Buckman, & Nguyen, 2013; Fals-Stewart & Lam, 2010; Rupp,
Kemmler, Kurz, Hinterhuber, & Fleischhacker, 2012; Verdejo-García, 2011; Wexler, 2011).
Further research aimed at developing and trialling cognitive remediation programs for AOD
populations is required and providing these interventions within residential treatment services
would be most ideal (e.g., Gonçalves et al., 2014).
4.3 Limitations and future directions
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There are several limitations of the current study. There were clear differences
between the AOD group and controls (e.g., age, education, inferred socioeconomic status).
While some of these differences were accounted for statistically, future research would
benefit from the inclusion of better-matched control groups. The exploration of primary
substance of misuse groups resulted in small sample sizes with reduced statistical power for
comparison; larger samples in future studies may reveal substance-specific impairment.
Another limitation of the current study is its failure to assess for psychiatric comorbidities,
which are common in AOD populations and add substantial complexity to the process of
treatment. The current study utilised the K10 as a measure of psychological distress and
higher scores were associated with greater cognitive impairment. Future studies should
include formal psychiatric diagnoses in order to examine their interaction with substance use
disorders and head injuries in terms of cognitive outcomes. Additionally, the current study
focused on hospitalisation and frequency of head injuries, but not their nature, severity or age
of occurrence, which could be further examined in future studies. Also, despite the AOD
sample being abstinent from AOD, there was no assessment of their duration of abstinence or
length of stay in residential services prior to cognitive assessment; this, along with a more
detailed substance use history (including age of onset and number of years of substance use)
and objective measures of abstinence (e.g. urine testing in both AOD and control samples),
could have provided further information regarding the nature and extent of the observed
cognitive deficits. Finally, the potential lack of sensitivity of the MoCA to more specific
cognitive deficits in AOD populations cannot be underestimated; the scores observed in this
sample were not substantially below the cut-off indicative of impairment. Nevertheless, the
MoCA can serve as a cost-effective screening tool that would detect severe deficits in those
most requiring further neurocognitive assessment.
4.4 Conclusion
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The current study identified that the MoCA may be usefully applied in the AOD
treatment setting as a brief screening tool. We showed in a naturalistic snapshot of clients in
AOD residential treatment that cognitive impairment is common and may be related to the
effects of head injuries, which are also highly prevalent. Cognitive abilities such as executive
function and working memory are important for AOD residents to engage meaningfully in
treatment and achieve successful outcomes. If these capacities are compromised, residents
may be more likely to drop out from treatment and fail to recover from their addiction. The
first step in rectifying this situation is to improve the assessment and detection of those who
present with cognitive deficits. This will help to inform modifications to treatment and/or
cognitive remediation interventions that may be beneficial in accommodating and potentially
remediating impairments in cognition, increasing the likelihood of treatment engagement and
retention, and hopefully leading to long-term recovery from addiction.
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